TREA

79285070 - BRIGHT PEAK

Follow

Information

  • Trademark
  • 79285070
  • Serial Number
    79285070
  • Registration Number
    6610085
  • Filing Date
    March 25, 2020
    5 years ago
  • Registration Date
    January 11, 2022
    3 years ago
  • Transaction Date
    July 18, 2022
    2 years ago
  • Status Date
    January 11, 2022
    3 years ago
  • Published for Opposition Date
    October 26, 2021
    3 years ago
  • Location Date
    January 11, 2022
    3 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    LAM, HAI-LY HUYNH
  • Attorney Docket Number
    4697.0010000
    Attorney Name
    MONICA RIVA TALLEY
    Law Office Assigned Location Code
    N10
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
BRIGHT PEAK
Case File Statements
  • GS0051: Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system, respiratory system, and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; medical and veterinary preparations, namely, recombinant or chemically synthesized and optimized proteins; preparations for destroying vermin; fungicides, herbicides; biotechnological preparations, namely, recombinant or chemically synthesized and optimized proteins for medical use; enzymes for medical use; enzymes for veterinary use; biological and chemical reagents for medical or veterinary use; amino acids for medical use; amino acids for veterinary use; peptides for medical or veterinary use, namely, for the treatment of cancer, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system, respiratory system, and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; proteins for medical or veterinary use, namely, recombinant or chemically synthesized and optimized proteins for detection and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, autoimmune diseases, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, nutritional diseases, mental and behavioral disorders, diseases of the nervous system, eye and adnexa, ear and mastoid process disorders, diseases of the circulatory system and digestive system, skin and subcutaneous tissue disorders, diseases of the musculoskeletal system and connective tissue, disorders and abnormalities relating to pregnancy and childbirth, certain conditions originating in the puerperium and perinatal periods, congenital malformations and deformations, and chromosomal abnormalities; pharmaceutical preparations for cancer treatment; biopharmaceutical preparations for cancer treatment; pharmaceutical compositions and preparations for cancer prevention and treatment; pharmaceutical preparations for treatment of autoimmune and inflammatory diseases; pharmaceutical preparations for treatment of skin diseases; pharmaceutical preparations for treatment of neurodegenerative, metabolic and ophthalmological diseases
  • GS0421: Scientific and technological services, namely, scientific research, scientific analysis, and scientific testing in the field of biotechnology and new product research and design services relating thereto; research and development in the field of biotechnology; consulting services in the field of biotechnology; scientific research services in the field of proteins, peptides and antibodies, and scientific advice relating thereto; scientific research services for medical purposes in the field of cancer and autoimmune diseases and scientific advice relating thereto
Case File Event Statements
  • 7/18/2022 - 2 years ago
    42 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 6/23/2022 - 2 years ago
    41 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 6/22/2022 - 2 years ago
    40 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 4/11/2022 - 3 years ago
    39 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 1/11/2022 - 3 years ago
    38 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 11/4/2021 - 3 years ago
    37 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 11/3/2021 - 3 years ago
    36 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 10/26/2021 - 3 years ago
    35 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 10/26/2021 - 3 years ago
    34 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/13/2021 - 3 years ago
    33 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 10/13/2021 - 3 years ago
    32 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 10/6/2021 - 3 years ago
    31 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 10/6/2021 - 3 years ago
    30 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 10/6/2021 - 3 years ago
    29 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 9/17/2021 - 3 years ago
    28 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 9/17/2021 - 3 years ago
    27 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 8/24/2021 - 3 years ago
    26 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 8/24/2021 - 3 years ago
    25 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 8/24/2021 - 3 years ago
    24 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 8/24/2021 - 3 years ago
    23 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 7/29/2021 - 3 years ago
    22 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/29/2021 - 3 years ago
    21 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/27/2021 - 3 years ago
    20 - ASSIGNED TO LIE Type: ALIE
  • 7/22/2021 - 3 years ago
    19 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 7/22/2021 - 3 years ago
    18 - EX PARTE APPEAL-INSTITUTED Type: EXPI
  • 7/22/2021 - 3 years ago
    17 - JURISDICTION RESTORED TO EXAMINING ATTORNEY Type: JURT
  • 7/22/2021 - 3 years ago
    16 - EXPARTE APPEAL RECEIVED AT TTAB Type: EXAF
  • 1/26/2021 - 4 years ago
    15 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 1/26/2021 - 4 years ago
    14 - FINAL REFUSAL E-MAILED Type: GNFR
  • 1/26/2021 - 4 years ago
    13 - FINAL REFUSAL WRITTEN Type: CNFR
  • 1/6/2021 - 4 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/5/2021 - 4 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/5/2021 - 4 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 8/7/2020 - 4 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 7/23/2020 - 4 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 7/23/2020 - 4 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 6/18/2020 - 4 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 6/17/2020 - 4 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/16/2020 - 4 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/12/2020 - 4 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 5/8/2020 - 4 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 5/7/2020 - 4 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR